Clinical Trials Browser

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

885 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Phase 2 Completed

64 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Phase 2 Completed

106 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT04510064 2025-03-12

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial

Phase 2 Completed

40 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Phase 2 Completed

35 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Phase 2 Completed

25 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Phase 2 Completed

39 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06376773 2024-04-19

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Completed

234 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed

600 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

NCT04694183 2024-02-07

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2 Completed

37 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2 Completed

28 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Phase 1 Completed

99 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03691090 2022-12-07

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Phase 3 Completed

596 enrolled

Gastrointestinal

Advanced Esophageal Cancer

NCT03755440 2022-09-21

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Phase 2 Completed

6 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04642664 2021-06-03

ACABC

Phase 2 Completed

22 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Phase 2 Completed

25 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

NCT03222440 2019-12-04

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Phase NA Completed

20 enrolled

Gastrointestinal

Esophageal Neoplasms